MabSwitch

MabSwitch is a preclinical-stage biotech pioneering a novel class of 'switchable' antibodies. Its core UNASMA™ technology inserts an allosteric switch module into antibodies, allowing their binding affinity to be turned ON or OFF via small molecules under physiological conditions. This platform has broad potential applications, including improving the safety profile of next-generation immunotherapies (like CAR-T cells and bispecifics) and creating reusable diagnostic and purification reagents. The company is currently in the technology development and validation phase, seeking to translate its platform into therapeutic and industrial partnerships.

UNASMA™ (Universal Allosteric-linker and Switch Module for Antibodies) – a platform to engineer regulatable antibodies by inserting a proprietary allosteric switch module that can be toggled ON or OFF using small molecule triggers, enabling reversible control of antibody affinity under physiological conditions.

MabSwitch operates in the competitive antibody engineering space, competing with companies developing alternative control modalities (e.g., masked antibodies, conditionally active biologics). Its unique approach of a small-molecule-triggered allosteric switch differentiates it, but it must demonstrate superior practicality and efficacy to gain traction.